<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00365768</url>
  </required_header>
  <id_info>
    <org_study_id>AAAA6806</org_study_id>
    <secondary_id>CPMC-ICCR-3349</secondary_id>
    <nct_id>NCT00365768</nct_id>
  </id_info>
  <brief_title>Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors</brief_title>
  <official_title>A Pilot Study Investigating the Effects of Glutamine and Vincristine-Induced Neuropathy in Pediatric Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Glutamine may help lessen neuropathy caused by chemotherapy. It is not yet known
      whether glutamine is more effective than a placebo in treating neuropathy caused by
      vincristine.

      PURPOSE: This randomized phase II trial is studying glutamine to see how well it works
      compared to a placebo in treating neuropathy caused by vincristine in young patients with
      lymphoma, leukemia, or solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the incidence of vincristine-induced peripheral neuropathy in pediatric
           patients with lymphoma, leukemia, or solid tumors.

      Secondary

        -  Compare the safety of glutamine vs placebo in these patients.

        -  Compare the efficacy of glutamine vs placebo in reducing the progression and/or
           resolution of vincristine-induced peripheral neuropathy in these patients.

        -  Compare the effect of glutamine supplementation vs placebo on chemotherapy-related
           toxicities in these patients.

        -  Compare the effect of glutamine vs placebo on measures of quality of life in these
           patients.

        -  Compare the effect of glutamine supplementation vs placebo on serum nerve growth factor
           and glutamine levels in these patients.

        -  Determine the effect of glutamine on vincristine-mediated antitumor efficacy in vitro.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, pilot study. Patients are
      randomized to 1 of 2 treatment arms.

        -  Arm I: Beginning 1 week after administration of vincristine chemotherapy, patients
           receive oral glutamine twice daily on days 1-21.

        -  Arm II: Beginning 1 week after administration of vincristine chemotherapy, patients
           receive oral placebo twice daily on days 1-21.

      Patients in both arms undergo neuropsychological and clinical neurological assessment, blood
      collection for serum marker (e.g., serum glutamine and nerve growth factor) analysis, and
      quality of life assessment on days 1, 21, and 42.

      After completion of study treatment, patients are followed for an additional 21 days.

      PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Vincristine-induced Peripheral Neuropathy</measure>
    <time_frame>Up to 30 weeks from baseline while on Vincristine treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Progression of Neuropathy</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Kidney Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Neurotoxicity</condition>
  <condition>Peripheral Neuropathy</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm I: Glutamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutamine</intervention_name>
    <description>Administered orally twice daily for 21 days</description>
    <arm_group_label>Arm I: Glutamine</arm_group_label>
    <other_name>Nutritional Supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally twice daily for 21 days</description>
    <arm_group_label>Arm II: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between the age of 5 and 21 years old.

          -  Patients who demonstrate the ability to complete the assessment instruments at
             baseline.

          -  Patients who are diagnosed with leukemia or solid tumors and are expected to receive a
             cumulative dose of &gt; or = to 6mg/m2 of vincristine, or &gt; 6mg if individual vincristine
             doses are capped at 2mg according to primary cancer treatment protocol, over a 30-week
             period.

        Exclusion Criteria:

          -  Patients with primary CNS tumors other than medulloblastoma or patients with CNS
             metastasis.

          -  Patients with recurrent disease.

          -  Patients with Grade II, III or IV neurological status by the NCI CTC (Ver. 3.0) on
             clinical exam.

          -  Patients who have already received &gt; 8mg/m2 of vincristine, or &gt; 8mg if individual
             vincristine doses are capped at 2mg according to primary cancer treatment protocol,
             during their course of therapy at time of consent.

          -  Patients with hepatic encephalopathy or hyperammonemia.

          -  Patients with a focally abnormal neurologic exam.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia L. Glade-Bender, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2006</study_first_submitted>
  <study_first_submitted_qc>August 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2006</study_first_posted>
  <results_first_submitted>November 6, 2015</results_first_submitted>
  <results_first_submitted_qc>July 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2016</results_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Julia Glade Bender</investigator_full_name>
    <investigator_title>Irving Assistant Professor of Clinical Pediatrics</investigator_title>
  </responsible_party>
  <keyword>stage II childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage II childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage I Wilms tumor</keyword>
  <keyword>stage II Wilms tumor</keyword>
  <keyword>stage III Wilms tumor</keyword>
  <keyword>stage IV Wilms tumor</keyword>
  <keyword>stage V Wilms tumor</keyword>
  <keyword>childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>stage I childhood large cell lymphoma</keyword>
  <keyword>stage I childhood lymphoblastic lymphoma</keyword>
  <keyword>stage I childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage II childhood large cell lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>childhood Burkitt lymphoma</keyword>
  <keyword>stage III childhood small noncleaved cell lymphoma</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>previously untreated childhood rhabdomyosarcoma</keyword>
  <keyword>localized Ewing sarcoma/PNET</keyword>
  <keyword>metastatic Ewing sarcoma/PNET</keyword>
  <keyword>neurotoxicity</keyword>
  <keyword>peripheral neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects were consented according to Institutional Review Board approved guidelines during out routine outpatient or inpatient stay. The period of recruitment was from January 2007 to July 2011.</recruitment_details>
      <pre_assignment_details>Fifty-six patients were enrolled and 49 were evaluable, with the reasons for removal from study after randomization due to: change in clinical status (N=3), family withdrew (N=2), family relocation (N=1) and other (N=1). 49 patients were randomized to the glutamine or placebo arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I: Glutamine</title>
          <description>Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.
Glutamine: Administered orally twice daily for 21 days</description>
        </group>
        <group group_id="P2">
          <title>Arm II: Placebo</title>
          <description>Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.
Placebo: Administered orally twice daily for 21 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Fifty-six patients were enrolled and 49 were evaluable.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I: Glutamine</title>
          <description>Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.
Glutamine: Administered orally twice daily for 21 days</description>
        </group>
        <group group_id="B2">
          <title>Arm II: Placebo</title>
          <description>Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.
Placebo: Administered orally twice daily for 21 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" lower_limit="5" upper_limit="19"/>
                    <measurement group_id="B2" value="10" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="B3" value="11" lower_limit="4" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Vincristine-induced Peripheral Neuropathy</title>
        <time_frame>Up to 30 weeks from baseline while on Vincristine treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I: Glutamine</title>
            <description>Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.
Glutamine: Administered orally twice daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Placebo</title>
            <description>Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.
Placebo: Administered orally twice daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Vincristine-induced Peripheral Neuropathy</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Progression of Neuropathy</title>
        <time_frame>42 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I: Glutamine</title>
            <description>Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.
Glutamine: Administered orally twice daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Placebo</title>
            <description>Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.
Placebo: Administered orally twice daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progression of Neuropathy</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I: Glutamine</title>
          <description>Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.
Glutamine: Administered orally twice daily for 21 days</description>
        </group>
        <group group_id="E2">
          <title>Arm II</title>
          <description>Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.
Placebo: Administered orally twice daily for 21 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julia Glade-Bender, MD</name_or_title>
      <organization>Columbia University Medical Center</organization>
      <phone>212-305-3379</phone>
      <email>jg589@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

